[Ip-health] FW: The Dangers of the Indian Government's Flirtation with U.S. Pharma and the Risks for India's Coherent, Pro-Public Health IP Policy
Michael H Davis
m.davis at csuohio.edu
Tue Oct 7 05:29:11 PDT 2014
This is such an old and universally rejected IP canard it is slightly embarrassing to hear the US is still using it.
The fact is that whether a country's patent system, especially of a less developed country, will attract industry or not is clearly that it won't. An inventor in India will still benefit from all the other country's patent systems whether or not his home country grants patents. Patent availability is not premised on residence nor the patent system any other country.
Thus if a company is attracted by India's economy or labor force or technical competence, its decision to invest could not reasonably be related to India's patent system. It will all enjoy all the international patent protections it would have had if it commercialized elsewhere.
The use of this argument reflects pharma's basic dishonesty and scorn for the public.
Prof. Mickey Davis
Cleveland State University
2121 Euclid Avenue, LB 234
Cleveland, OH 44115-2214
Cleveland-Marshall College of Law
1801 Euclid Avenue
Law Building, LB 234
Admitted to practice before the United States Patent and Trademark Office, Reg. No. 45,863
-------- Original message --------
From: "Baker, Brook"
Date:10/07/2014 2:11 AM (GMT-05:00)
To: IP-health ,iplusa ,healthgap at lists.critpath.org,internationaltreatmentpreparedness at yahoogroups.com
Subject: [Ip-health] FW: The Dangers of the Indian Government's Flirtation with U.S. Pharma and the Risks for India's Coherent, Pro-Public Health IP Policy
...U.S. business interests and government officials are trying to sell the idea that heightened intellectual property protections in India are
essential to foreign investment, innovation, and achievement of public health goals.
Instead, heightened intellectual property rights will make India consumers captive to Big Pharma?s extortionate pricing....
Unfortunately, the joint communiqué issued at the end of Prime Minister Modi?s US visit shows deference by the US and Indian
governments to Big Pharma's pressure...
The Dangers of the Indian Government's Flirtation with U.S. Pharma and the Risks for India's Coherent, Pro-Public Health IP Policy
Professor Brook K. Baker, Senior Policy Analyst Health GAP
October 5, 2014
Ip-health mailing list
Ip-health at lists.keionline.org
More information about the Ip-health